Tesamorelin and Liver Fat: MASH Research
Tesamorelin
37% Liver Fat Reduction
Tesamorelin reduced hepatic fat fraction by 37% relative to baseline in HIV-infected patients with NAFLD, with 35% of treated patients dropping below the 5% fat threshold that defines fatty liver disease.
Stanley et al., Lancet HIV, 2019
Stanley et al., Lancet HIV, 2019
View as imageTesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) approved by the FDA in 2010 for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Its liver fat data comes from an unexpected direction: researchers studying tesamorelin's visceral fat-reducing effects noticed that liver fat also decreased, sometimes dramatically. Subsequent randomized trials in HIV-associated NAFLD showed a 37% relative reduction in hepatic fat fraction, with 35% of treated patients resolving fatty liver entirely, and strikingly, only 10% of tesamorelin-treated patients showed fibrosis progression versus 37% on placebo.
These findings are notable because tesamorelin is already approved, already on the market, and already being prescribed, a different starting position from the pipeline drugs (survodutide, resmetirom) that dominate MASH discussion. For the broader tesamorelin profile, see Tesamorelin (Egrifta): The FDA-Approved GHRH Analog.
Key Takeaways
- Stanley et al. (2019) showed tesamorelin reduced hepatic fat fraction by 37% vs placebo in HIV-associated NAFLD (Lancet HIV); 35% of tesamorelin-treated patients no longer met criteria for fatty liver disease at 12 months vs 4% on placebo
- Fibrosis progression occurred in only 10% of tesamorelin recipients vs 37% of placebo recipients, making tesamorelin the only agent shown to reduce fibrosis progression specifically in HIV-associated liver disease
- Tesamorelin's liver fat reduction is mediated through growth hormone: GH increases hepatic lipid oxidation, reduces de novo lipogenesis, and promotes triglyceride export from hepatocytes via VLDL secretion
- Transcriptomic analysis (JCI Insight, 2020) showed tesamorelin increased hepatic expression of oxidative phosphorylation genes and decreased expression of inflammatory and fibrotic gene sets, explaining the histological improvements
- Badran et al. (2026) confirmed the body composition, hepatic fat, and metabolic benefits of tesamorelin in INSTI-treated persons with HIV, extending the evidence to current antiretroviral regimens
- Unlike GLP-1 agonists that reduce liver fat primarily through weight loss and insulin sensitization, tesamorelin acts through a distinct GH-mediated mechanism that directly promotes hepatic fat burning, raising the question of whether the two approaches might be complementary
How tesamorelin reduces liver fat
Tesamorelin is a 44-amino-acid GHRH analog (endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus) that stimulates pituitary growth hormone release. The mechanism by which increased GH reduces liver fat involves three pathways.
Increased hepatic lipid oxidation. Growth hormone activates STAT5 signaling in hepatocytes, which upregulates genes involved in fatty acid beta-oxidation. Fat stored as triglycerides in liver cells is broken down and burned for energy. This was confirmed at the molecular level by transcriptomic analysis of liver biopsies from tesamorelin-treated patients, which showed increased expression of oxidative phosphorylation gene sets.
Reduced de novo lipogenesis. GH signaling suppresses the expression of SREBP-1c and other lipogenic transcription factors that drive the synthesis of new fat from carbohydrate precursors. With less new fat being produced and more existing fat being oxidized, the net hepatic fat balance shifts toward depletion.
Enhanced VLDL secretion. Growth hormone promotes the assembly and secretion of very-low-density lipoproteins (VLDL) from hepatocytes, exporting triglycerides from the liver into the circulation where they can be used by peripheral tissues for energy. This "fat export" mechanism complements the increased oxidation.
Stanley et al. (2021) documented that GHRH reduces circulating markers of immune activation in HIV, suggesting that tesamorelin's benefits may extend beyond fat metabolism to include anti-inflammatory effects relevant to the chronic low-grade inflammation that characterizes MASH.[1]
The HIV-associated NAFLD trials
The pivotal 2019 Lancet HIV study
Stanley et al. published the definitive trial in the Lancet HIV (2019). This was a randomized, double-blind, multicenter trial that enrolled 61 HIV-infected patients with NAFLD (hepatic fat fraction above 5% by MRI) to receive tesamorelin 2 mg or placebo via daily subcutaneous injection for 12 months. Liver biopsies were performed at baseline and at study end.
Primary endpoint: Tesamorelin reduced hepatic fat fraction by an absolute 4.1 percentage points more than placebo (p = 0.02), corresponding to a 37% relative reduction from baseline. The placebo group showed no change.
Resolution of NAFLD: 35% of tesamorelin-treated patients dropped below the 5% hepatic fat fraction threshold (no longer qualifying as NAFLD) vs 4% on placebo.
Fibrosis progression: This was the most clinically important finding. Fibrosis stage (assessed by liver biopsy) progressed in 37% of placebo recipients over 12 months but in only 10% of tesamorelin recipients. Fibrosis stage is the single strongest predictor of liver-related mortality in NAFLD/MASH, making prevention of fibrosis progression a critical clinical endpoint.
Transcriptomic data: Liver biopsy RNA sequencing showed that tesamorelin treatment upregulated oxidative phosphorylation pathways and downregulated inflammatory, tissue repair, and cell division gene sets. This molecular signature is consistent with a shift from steatohepatitis (active inflammation and fibrogenesis) toward metabolic resolution.
The INSTI-era extension
Badran et al. (2026) studied tesamorelin in HIV patients treated with integrase strand transfer inhibitors (INSTIs), the current standard first-line antiretroviral class. INSTIs (dolutegravir, bictegravir) are associated with weight gain and visceral fat accumulation, creating a modern version of the lipodystrophy problem. In this population, tesamorelin reduced visceral adipose tissue by 8.3% (vs a 10.8% increase in placebo) and reduced hepatic fat fraction by 31% relative to baseline, confirming that the liver fat benefit extends to current treatment regimens.[2]
Makimura et al. (2014) had earlier studied tesamorelin's effects on muscle metabolism, finding that the drug improved phosphocreatine recovery (a measure of mitochondrial function) in obese subjects. This suggests that tesamorelin's metabolic effects extend beyond the liver to include systemic improvements in cellular energy metabolism.[3]
Tesamorelin vs other MASH approaches
The MASH treatment landscape has expanded rapidly, with multiple mechanisms now showing efficacy. Tesamorelin's position in this landscape is unique but narrow.
Resmetirom (Rezdiffra): FDA-approved in 2024 for MASH with moderate-to-advanced fibrosis. Works through thyroid hormone receptor beta agonism. Directly activates hepatic lipid metabolism without involving GH. The only drug with full FDA approval for MASH.
Survodutide: GLP-1/glucagon dual agonist with phase 2 MASH data showing 62% resolution at the highest dose. Reduces liver fat through both GLP-1-mediated weight loss and glucagon-mediated hepatic lipid oxidation. In phase 3 trials. For details, see Survodutide Clinical Trial Data: Weight Loss and Metabolic Outcomes.
GLP-1 agonists (semaglutide, tirzepatide): Reduce liver fat primarily through weight loss and insulin sensitization. Mantovani et al. (2025) conducted a meta-analysis confirming that GLP-1 RAs improve MASH and liver fibrosis, though the effect is less pronounced than with agents that directly target hepatic metabolism.[4]
Tesamorelin: Works through GH-mediated hepatic lipid oxidation. Only studied in HIV-associated NAFLD. Not FDA-approved for MASH. Its advantage is that it is already available and its mechanism (GH stimulation) is distinct from every other MASH approach, raising the possibility of combination therapy.
The off-label question
Tesamorelin is currently prescribed off-label for MASH and metabolic optimization in non-HIV populations through anti-aging and wellness clinics. This practice extrapolates from HIV-specific trial data to the general population, an evidence leap that has not been validated in a randomized trial.
The key question is whether tesamorelin's liver fat-reducing effects in HIV patients, who have a specific form of metabolic dysfunction driven by viral proteins, antiretroviral drug effects, and chronic immune activation, translate to the non-HIV population with MASH. The underlying biology suggests it should: the GH-mediated pathways that oxidize liver fat are not HIV-specific. But the regulatory and evidence bar requires dedicated trials.
A prospective phase 2 trial of tesamorelin in non-HIV NAFLD (NCT03375788) is registered, but complete results have not been published. Until that data is available, the non-HIV liver fat application remains evidence-adjacent but not evidence-proven.
For the broader GHRH analog landscape, see the CJC-1295 articles in the Growth Hormone Peptides cluster. For how tesamorelin's lipodystrophy approval came about, see Tesamorelin and HIV Lipodystrophy: Why It Was Developed.
Combination potential
The distinct mechanism of tesamorelin (GH-mediated hepatic lipid oxidation) is non-overlapping with GLP-1 agonist mechanisms (appetite suppression, insulin sensitization) and with resmetirom's mechanism (thyroid hormone receptor beta agonism). This suggests potential for combination therapy.
Harrison et al. (2025) studied the combination of efruxifermin (an FGF21 analog) with a GLP-1 receptor agonist for MASH, demonstrating that combining agents with complementary mechanisms produces additive hepatic benefits. The same logic would apply to tesamorelin + GLP-1 RA or tesamorelin + resmetirom combinations, though neither has been tested.[5]
Cui et al. (2018) showed that GHRH and its agonists inhibit hepatic tumor growth, an additional consideration for MASH patients who are at elevated risk of hepatocellular carcinoma. Whether tesamorelin's GH-stimulating properties provide any hepatoprotective benefit against cancer progression in the MASH population is speculative but biologically plausible.[6]
The Bottom Line
Tesamorelin is the only FDA-approved GHRH analog and has demonstrated a 37% relative reduction in liver fat, resolution of NAFLD in 35% of treated patients, and dramatic reduction in fibrosis progression (10% vs 37% placebo) in HIV-associated liver disease. The mechanism (GH-mediated hepatic lipid oxidation, reduced lipogenesis, enhanced VLDL export) is distinct from every other MASH approach in development. The limitation is that all controlled efficacy data comes from HIV-positive populations; the non-HIV MASH application relies on mechanistic extrapolation pending dedicated trial results. Tesamorelin's existing availability and unique mechanism position it as a potential combination partner with GLP-1 agonists or other MASH agents.